340B Drug Discount Program


In 1992, the federal government created the 340B drug discount program that requires drug manufacturers to provide outpatient drugs to eligible health care organizations at reduced pricing. Maury Regional Medical Center meets the eligibility criteria to participate in this program.

Value of the Program

Maury Regional Health is committed to using the 340B program for its intended purpose: to provide enhanced access to health care and medications. We are also committed to the American Hospital Association’s good stewardship principles and publish on an annual basis how we use 340B savings to benefit the community. 

Community Outreach

Below is a partial summary of Maury Regional Health’s outreach to the community, in part as a result of the 340B program:

  • Cost of charity care and bad debt: $13,851,586
  • Free health care for Maury County Jail inmates: $502,948
  • Support for Maury County school athletic trainers: $205,270
  • Additional community services: $411,137

Expanded Access to Medications:

Maury Regional Health’s 340B Program enables the following services and expands access to medications:

  • Maury Regional Cancer Center has offered cancer treatment to patients who otherwise would not have been able to afford treatment.
  • Meds to Beds Program allows patients to receive medication counseling and delivery prior to discharge.
  • Medical Mission event in Hohenwald held September 28, 2019, included a medical and dental clinic that offered free access to prescription drugs for vulnerable populations in rural Tennessee.
  • Maury Regional Health Care Foundation's Special Needs Fund assists at-risk patients with free medications.

These services would not be able to continue without the savings that the 340B program has provided.

Estimated Savings

Maury Regional Health is committed to publicly disclosing its 340B estimated savings on an annual basis using a standardized method. 

Fiscal Year 2019

  • 340B Savings: $6,659,986.83
  • Top Ten Drugs for 340B Savings: Ketruda, Gamunex-C, Ocrevus, Neulasta Onpro Kit, Imfinzi, Darzalex, Entyvio, Remicade and Xgeva


Maury Regional Health is committed to continuing management of internal reviews; thereby ensuring the hospital’s 340B program meets Health Resources and Services Agency (HRSA) program rules and guidance. Maury Regional Health internal oversight includes:

  • Self-auditing by pharmacy
  • Educational seminars and remote training for appropriate staff members  
  • Periodic auditing by Maury Regional's internal Audit Department and/or external auditor
  • Oversight by senior leadership, pharmacy, finance and legal departments